Composition containing ethyl vanillin as an active ingredient for enhancing muscle strength, increasing muscle mass, promoting muscle differentiation, facilitating muscle regeneration, or inhibiting sarcopenia.

Ethyl vanillin-based composition for inhibiting sarcopenia and enhancing muscle strength

This technology utilizes ethyl vanillin, a widely used flavoring agent, or its salts as an active ingredient to prevent and treat muscle diseases, while promoting muscle differentiation, regeneration, and muscle mass increase. It can be utilized in both pharmaceutical and dietary supplement forms.

The aging population has led to an increase in patients with geriatric sarcopenia, which not only causes gait impairment but also elevates the risk of diabetes and cardiovascular disease. However, there are currently no approved drugs for treating sarcopenia, and research into myostatin inhibitors or drug repurposing remains in the developmental stage.

This technology leverages the dual action of ethyl vanillin, which increases the expression of muscle protein synthesis signals p-4E-BP1 and p-p70S6K, while inhibiting the expression of muscle degradation-related factors MuRF1, MaFbx, and myostatin. It can be applied to treatments for geriatric sarcopenia, muscle atrophy, and cachexia, as well as muscle-strengthening dietary supplements, reducing development risks by using a food additive with proven safety.

‍

‍

Key Features:

• Pharmaceutical composition for preventing or treating muscle diseases comprising ethyl vanillin or a pharmaceutically acceptable salt as an active ingredient
• Composition containing ethyl vanillin that promotes p-4E-BP1 and p-p70S6K protein expression or inhibits MuRF1, MaFbx, or myostatin expression
• Pharmaceutical composition targeting one or more of muscle atrophy, muscular dystrophy, cachexia, ALS, and sarcopenia
• Health functional food composition containing ethyl vanillin as an active ingredient for promoting muscle differentiation, increasing muscle mass, or improving muscle function

‍